Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis

Published:2024-07-29 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Hu Qingjie¹^ORCID,Gao Yingxia¹^ORCID,Xu Kang²,Yao Xu¹^ORCID

Affiliation:

1. Department of Allergy and Rheumatology Hospital of Skin Disease (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China

2. Department of Pharmacy Hospital of Skin Disease (Institute of Dermatology), Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20265

Reference8 articles.

1. Real-world persistence with dupilumab among adults with atopic dermatitis

2. Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients

3. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

4. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

5. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP